Journal article
Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy
A Emmanouilidi, I Casari, BG Akkaya, T Maffucci, L Furic, F Guffanti, M Broggini, X Chen, YY Maxuitenko, AB Keeton, GA Piazza, KJ Linton, M Falasca
Cancers | MDPI | Published : 2020
Open access
Abstract
Expression of ATP-binding cassette (ABC) transporters has long been implicated in cancer chemotherapy resistance. Increased expression of the ABCC subfamily transporters has been reported in prostate cancer, especially in androgen-resistant cases. ABCC transporters are known to efflux drugs but, recently, we have demonstrated that they can also have a more direct role in cancer progression. The pharmacological potential of targeting ABCC1, however, remained to be assessed. In this study, we investigated whether the blockade of ABCC1 affects prostate cancer cell proliferation using both in vitro and in vivo models. Our data demonstrate that pharmacological inhibition of ABCC1 reduced prostate..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This research was funded by Prostate Cancer UK (grant PG12-23 to M.F.). Research reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under awards R01CA197147 and R01CA131378.